RET and medullary thyroid gland carcinoma: In a larger phase 3 trial, cabozantinib appeared to prolong PFS vs placebo in the RET mutation-positive subgroup of patients with radiologically documented progressive MTC (HR: 0.23; 95% CI: 0.14–0.38; P  < 0.0001), in the RET mutation-unknown subgroup (HR: 0.30; 95% CI: 0.16–0.57; P = 0.0001) and in the RAS mutation-positive subgroup (HR: 0.15; 95% CI: 0.02–1.10; P = 0.0317).